Stock Analysis

Beamtree Holdings Full Year 2025 Earnings: Revenues Miss Expectations

Advertisement

Beamtree Holdings (ASX:BMT) Full Year 2025 Results

Key Financial Results

  • Revenue: AU$25.0m (down 9.4% from FY 2024).
  • Net loss: AU$6.20m (loss widened by 21% from FY 2024).
earnings-and-revenue-growth
ASX:BMT Earnings and Revenue Growth August 29th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beamtree Holdings Revenues Disappoint

Revenue missed analyst estimates by 5.9%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia.

Performance of the Australian Healthcare Services industry.

The company's shares are down 9.6% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Beamtree Holdings that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Beamtree Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ASX:BMT

Beamtree Holdings

Provides artificial intelligence-based decision support software and data insight solutions, and other software services to the healthcare industry in Australia and internationally.

Good value with adequate balance sheet.

Advertisement

Updated Narratives

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25158.0% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5032 logo
MarkoVT on ANYCOLOR ·

Near zero debt, Japan centric focus provides future growth

Fair Value:JP¥7.61k15.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
TAVHL logo
composite32 on TAV Havalimanlari Holding ·

TAV Havalimanlari Holding will fly high with 25.68% revenue growth

Fair Value:₺545.1648.6% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
93 users have followed this narrative
10 users have commented on this narrative
18 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.9% undervalued
136 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$232.7922.6% undervalued
929 users have followed this narrative
6 users have commented on this narrative
22 users have liked this narrative